ArticleEMBO molecular medicine2022
SARS-CoV-2 Omicron emergence urges for reinforced One-Health surveillance.
Article in EMBO molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tracing the origin of Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): A systematic review and narrative synthesis.Journal of medical virology · 2022Pooled it
- Infection of urban rodents by SARS-CoV-2 in COVID-19 healthcare facilities in Brazzaville, Republic of the Congo.One health outlook · 2026Article
- One Health serosurveillance of anti-SARS-CoV-2 antibodies in domestic animals from the metropolitan area of Panama.Veterinary world · 2025Article
- One Health integrated surveillance: a way forward to accelerate schistosomiasis elimination in China.Science in One Health · 2025Review
- Lung infection in orally inoculated SARS-CoV-2 hamsters.PloS one · 2025Article
- Article
- Distinct phenotype of SARS-CoV-2 Omicron BA.1 in human primary cells but no increased host range in cell lines of putative mammalian reservoir species.Virus research · 2024Article
- Domestic and wild animal samples and diagnostic testing for SARS-CoV-2.The veterinary quarterly · 2023Review
- Review
- The recombinant variants of SARS-CoV-2: Concerns continues amid COVID-19 pandemic.Journal of medical virology · 2022Article
- SARS-CoV-2 wildlife surveillance in Ontario and Québec.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2022Article
- SARS-CoV-2 Omicron emergence urges for reinforced One-Health surveillance.EMBO molecular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
SARS-CoV-2 Omicron harbors substitutions in the receptor binding domain of the spike which strongly suggest its capacity to infect rodents. Wild animal reservoirs could favor the emergence of new variants with risks of spillback to humans and should be closely monitored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.